Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib in Anemia Due to Low-risk Myelodysplastic Syndrome
NCT06847867Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of mivavotinib in myelodysplastic syndrome (MDS), sponsored by GSK. Started Jun 2025; status: recruiting.
02
Drugs
mivavotinib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06847867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847867.